FRANKFURT (Reuters) – Bayer’s finance chief said on Wednesday that the drugs and pesticides maker would remain very selective when considering any further settlements of U.S. litigation cases in which plaintiffs blame their cancer on Bayer’s Roundup weedkiller.
“We have no appetite to write humongous checks,” said CFO Wolfgang Nickl in a media call after the release of third-quarter results. He added that Bayer has sound legal and scientific arguments to pursue its cases and appeals in court.
Last week, a California jury found Bayer liable in a case brought by a man who claimed his cancer was due to exposure to the company’s glyphosate-based Roundup, the third consecutive defeat for Bayer. Before that, Bayer had won nine cases in a row.
(Reporting by Ludwig Burger; Editing by Miranda Murray)
